NOVO NORDISK A S
Close on Oct 19, 2026
About Novo Nordisk A S
Pharmaceutical Preparations, SIC 2834
Novo Nordisk A/S is a global healthcare company specializing in the discovery, development, manufacturing, and marketing of pharmaceutical products. The company operates primarily through two core segments: Obesity and Diabetes care, and Rare disease. Its portfolio features glucagon-like-peptide-1 (GLP-1) receptor agonists and insulins for metabolic conditions, alongside treatments for haemophilia and growth hormone deficiencies. These prescription medicines and medical devices primarily serve patients living with chronic conditions, as well as healthcare practitioners and clinical facilities.
Headquartered in Bagsværd, Denmark, the enterprise distributes and markets its medical products across approximately 170 countries. The organization employs more than 69,500 personnel across roughly 80 nations globally. Its network of primary manufacturing facilities and active pharmaceutical ingredient sites spans multiple countries, including Denmark, the United States, France, China, Brazil, Italy, and Belgium.
Summary of the business section of Novo Nordisk A S's latest annual report, written by StockData.
Company profile
Company
- Legal name
- NOVO NORDISK A S
- Founded
- 1923
- Headquarters
- Bagsvaerd Denmark, G7
- Address
- Novo Alle Dk 2880 00000
- Phone
- (454) 444-8888
- Employees
- 69,505, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Deloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark
Stock & identifiers
- Ticker
- NVO
- Other tickers
- NONOF
- Exchange
- NYSE
- IPO date
- Apr 30, 1981
- Shares outstanding
- 4.46B, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 2-for-1, Jan 31, 2024; 2-for-1, Sep 20, 2023; 2-for-1, Sep 13, 2023; 5-for-1, Jan 9, 2014; 5-for-1, Jan 2, 2014; 2-for-1, Dec 17, 2007; 5-for-2, Apr 11, 2001; 4-for-1, Apr 18, 1994
- SEC CIK
- 353278
- CUSIP
- 670100205
- ISIN
- US6701002056
- LEI
- 549300DAQ1CVT6CXN342
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Novo Nordisk A S's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Sep 15, 2022 | Tender offer | Third-party tender offer for the company's shares |
| Nov 24, 2021 | Tender offer | Third-party tender offer for the company's shares |